Vimarsana
Biggest News Aggregation in the World

Acting Properties News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acting Properties. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acting Properties Today - Breaking & Trending Today

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen - Vimarsana News

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA...

U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment - Vimarsana News

U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label...

Johnson & Johnson : U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment - Vimarsana News

Johnson & Johnson : U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment

Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first TITUSVILLE, N.J., March 24, 2022 - The Janssen... | March 24, 2022

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period - Vimarsana News

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections For media and investors

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022 - Vimarsana News

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022Data reinforce ViiV Healthcare’s leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention London, 7 February 2022 – ViiV Healthca...